Switch theme
Sign up to access all valuation multiples
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. Orion mainly serves Finland but also has a presence in other European countries, North America and other countries.
2006
3.7K+
LTM Revenue $1.8B
LTM EBITDA $590M
$9.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orion has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of $590M.
In the most recent fiscal year, Orion achieved revenue of $1.7B and an EBITDA of $577M.
Orion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Profit | $917M | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $590M | XXX | $577M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $478M | XXX | $466M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $382M | XXX | $371M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $124M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Orion's stock price is EUR 60 (or $67).
Orion has current market cap of EUR 8.4B (or $9.4B), and EV of EUR 8.4B (or $9.5B).
See Orion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.5B | $9.4B | XXX | XXX | XXX | XXX | $2.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Orion has market cap of $9.4B and EV of $9.5B.
Orion's trades at 5.5x EV/Revenue multiple, and 16.4x EV/EBITDA.
Equity research analysts estimate Orion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Orion has a P/E ratio of 24.7x.
See valuation multiples for Orion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.4B | XXX | $9.4B | XXX | XXX | XXX |
| EV (current) | $9.5B | XXX | $9.5B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.1x | XXX | 16.4x | XXX | XXX | XXX |
| EV/EBIT | 19.8x | XXX | 20.4x | XXX | XXX | XXX |
| EV/Gross Profit | 10.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.7x | XXX | 25.4x | XXX | XXX | XXX |
| EV/FCF | 33.2x | XXX | 40.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrion's last 12 month revenue growth is 12%
Orion's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Orion's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orion's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Orion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orion acquired XXX companies to date.
Last acquisition by Orion was XXXXXXXX, XXXXX XXXXX XXXXXX . Orion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Orion founded? | Orion was founded in 2006. |
| Where is Orion headquartered? | Orion is headquartered in Finland. |
| How many employees does Orion have? | As of today, Orion has 3.7K+ employees. |
| Who is the CEO of Orion? | Orion's CEO is Ms. Liisa Hurme, PhD. |
| Is Orion publicy listed? | Yes, Orion is a public company listed on HEL. |
| What is the stock symbol of Orion? | Orion trades under ORNAV ticker. |
| When did Orion go public? | Orion went public in 2006. |
| Who are competitors of Orion? | Similar companies to Orion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Orion? | Orion's current market cap is $9.4B |
| What is the current revenue of Orion? | Orion's last 12 months revenue is $1.8B. |
| What is the current revenue growth of Orion? | Orion revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Orion? | Current revenue multiple of Orion is 5.3x. |
| Is Orion profitable? | Yes, Orion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Orion? | Orion's last 12 months EBITDA is $590M. |
| What is Orion's EBITDA margin? | Orion's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Orion? | Current EBITDA multiple of Orion is 16.1x. |
| What is the current FCF of Orion? | Orion's last 12 months FCF is $286M. |
| What is Orion's FCF margin? | Orion's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Orion? | Current FCF multiple of Orion is 33.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
